Skip Navigation
Search Menu
Find an Expert


Photo of Dr. Thomas Donner

Thomas W Donner, M.D.

Director, Johns Hopkins Diabetes Center
Associate Professor of Medicine


Appointment Phone


Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Director, Johns Hopkins Diabetes Center
  • Associate Professor of Medicine



The Johns Hopkins Hospital

Appointment Phone: 410-955-9270

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Phone: 410-955-2908
Fax: 410-614-9586

Johns Hopkins Outpatient Center

Appointment Phone: 410-955-9270

601 N. Caroline Street
Baltimore, MD 21287 map
Phone: 410-955-2908
Fax: 410-614-9586

Contact for Research Inquiries

Baltimore, MD 21205 map
Phone: 443-287-7843


Diabetes and Cardiovascular Diseases, Endocrinology

Research Interests

Type 1 Diabetes; Insulin Therapy; Immunotherapy


Dr. Donner's clinical and research interests have focused on the prevention of complications in patients with type 1 and 2 diabetes. For 6 years, he was the Associate Medical Director of the Joslin Diabetes Center affiliate at the University of Maryland, and then Medical Director from 2004 - 2010. After joining the faculty at Johns Hopkins University in 2010, his clinical and research interests became fully dedicated to diabetes. He became the Director of The Johns Hopkins Diabetes Center in 2011. He has been a clinical investigator in a number of NIH- and industry-funded diabetes research trials. Dr. Donner was a co-PI in the NIH-funded Veterans Affairs Implantable Insulin Pump Study, a Co-PI on the NIDDK-funded Diabetes Control and Complications Trial / Epidemiology of Diabetes Intervention and Complications (DCCT / EDIC) Study for 16 years, and Co-PI for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) for 7 years. Recently, he has served as PI for the Durable-response therapy Evaluation For Early or New-onset type 1 Diabetes (DEFEND-1). Dr. Donner is currently collaborating with Dr. Abdel Hamad in Immunology on preventing B-regulatory cell apoptosis using a novel monoclonal antibody targeting the presumptive apoptotic factor. This antibody prevents the development of type 1 diabetes in non obese diabetic mice. Dr. Donner is the PI for Johns Hopkins for TrialNet, a multicenter, international consortium of investigators studying ways to prevent Type 1 diabetes and preserve insulin secretion in individuals with newly diagnosed Type 1 diabetes. He is also a PI for a study investigating FIAsp, a faster-acting insulin aspart in subjects with type 1 diabetes, and is working with investigators at the Johns Hopkins School of Engineering on an implantable insulin pump which delivers insulin intravenously. more

    Additional Information

  • Education +


    • University of Virginia School of Medicine / MD (1986)


    • University of Maryland Medical Center / Internal Medicine (1989)
    • University of Maryland Medical Center / Internal Medicine (1994)


    • University of Maryland Medical Center / Endocrinology (1993)


    • American Board of Internal Medicine / Endocrinology (1991, 2007)
    • American Board of Internal Medicine / Internal Medicine (1989)
  • Research & Publications +

    Research Summary

    Dr. Donner's clinical and research interests include aggressive management of type 1 and type 2 diabetes, preserving beta cell function in patients with new onset type 1 diabetes, and the prevention of diabetes complications.

    Clinical Trials:

    1. 1R01AI099027-01 NIH/NIAID Hamad (PI) 03/01/13 - 03/31/18

    Mechanisms of Fas Ligand control of insulitis initiation in autoimmune diabetes

    Role: Co-investigator

    2. NIDDK Donner (PI) 05/13 – present

    The Natural History Study of the Development of Type 1 Diabetes

    Role: PI

    3. NovoNordisk Donner (PI) 10/13 - present

    Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

  • Academic Affiliations & Courses +
  • Activities & Honors +


    • American Diabetes Association
    • Endocrine Society
  • Videos & Media +
Is This You? Edit Profile